Eltrombopag is an oral thrombopoietin receptor agonist that increases platelet counts by stimulating the differentiation and proliferation of megakaryocytes.
The dosing schedule is dependent on the individual patient's platelet counts but consists of a once daily oral dose.
The objective of treatment with eltrombopag is to maintain platelet counts above the level for haemorrhagic risk (50000/microlitre).
In most patients, measurable elevations in platelet counts take 1-2 weeks.
Further information: GSK